The way some doctors handle Ozempic and other GLP-1 weight-loss medications raises serious concerns. And health influencers often make matters worse by spreading misleading information that leaves people confused about real risks and genuine benefits.
When handled correctly, GLP-1 medications can be a genuine turning point for people living with obesity. This article provides evidence-based information about these therapies and explains what appropriate medical oversight looks like — so readers can make a well-informed decision about whether they may be a suitable option for themselves or a loved one. By the end, the goal is to have a clear, accurate picture of both the evidence and the questions to ask any prescribing physician.
Table of Contents
Section 1: Prescribing Malpractice
Section 2: Common Misconceptions
Section 3: Risk and Benefit in Context
Section 4: Tirzepatide — The Newer Option
Section 1: Prescribing Malpractice
Some physicians ignore the clinical guidelines for providing proper care to patients seeking weight-loss treatment. This is a serious problem — and understanding what best-practice GLP-1 prescribing looks like makes it easier to identify when those standards are not being met. (If a prescriber exhibits any of the issues described below, that is a reasonable basis for seeking a different doctor.)
The clinical guidelines specify several steps that doctors should follow before prescribing GLP-1 medications like Ozempic:
1. Assess BMI and health risks: A doctor should assess a patient's body mass index (BMI), waist circumference, and other health comorbidities before any prescribing discussion begins.
2. Set realistic goals: Weight loss goals should be discussed in detail — and they should be realistic, specific, and tailored to the individual.
3. Recommend lifestyle changes: Appropriate lifestyle changes should be identified and supported, always involving diet adjustment and increased physical activity. Medication should complement this work, not replace it.
4. Wait 3–6 months: The patient should be given 3–6 months to implement and evaluate those lifestyle changes before medication is considered.
5. Consider medication: In most cases, beginning a medication like Ozempic is only appropriate when a patient has a BMI over 30 and has not met weight loss goals despite sustained lifestyle effort — and only after thoroughly ensuring the patient understands the risks, the benefits, and the long-term nature of treatment.
What is happening in some clinics instead is deeply concerning. Some doctors issue prescriptions for GLP-1 medicines after patients complete a short online questionnaire. If certain qualifications are met, a prescription for Ozempic is written — sometimes for $50–$200 per script — with little meaningful assessment and no ongoing support. That is not medicine.
Many physicians also fail to tell patients about a key aspect of using GLP-1 medications for weight loss. Specifically, they do not explain that these medications generally need to be used long-term. Studies show weight will usually return if patients stop using them [1].
It is essential for patients to know this upfront so they can properly weigh the benefits and potential risks of the medication — especially when considering the costs, because these medications are not cheap and coverage varies significantly by insurer and country.
Finally, some doctors do not monitor patients taking GLP-1 medications adequately. This failure tends to be most common among the same doctors who prescribe without following clinical guidelines. At best, they might schedule a periodic telehealth consultation and leave patients largely unsupported.
As with any medication, there are potentially serious adverse effects with this class of treatment. Careful, ongoing monitoring is not optional — it exists precisely to detect and respond to problems before they become serious.
GLP-1 medications are a powerful therapeutic tool. But they need to be used judiciously, within a proper clinical framework. Patients considering a GLP-1 medication like Ozempic should look for a prescriber who genuinely follows best-practice guidelines, provides full counselling about risks and the long-term nature of treatment, and commits to regular monitoring. Beginning a prescription medication is a serious decision that deserves proper medical support throughout — not just a rubber-stamp and a monthly charge.
Section 2: Common Misconceptions
There are real potential adverse effects with Ozempic and similar medications. But there are also significant misconceptions circulating — particularly from social media influencers — that have caused unnecessary alarm or, in other cases, unfounded reassurance. What follows is a direct examination of the five most commonly raised concerns, based on the current published evidence.
1. Muscle Loss
The first misconception concerns muscle. The concern is that GLP-1 medications cause significant lean muscle loss — to a degree that outweighs their weight-loss benefit [2].
The evidence confirms: yes, some lean mass is lost with GLP-1 medications — but this is not unique to them. Losing muscle is a normal consequence of weight loss by any method, whether through dietary changes alone, medications, or bariatric surgery. When caloric intake falls below expenditure, the body draws energy from stored fat and, to some extent, from muscle tissue as well. This is a fundamental metabolic reality, not a pharmacological side effect specific to GLP-1 drugs.
The more precise and relevant question is: Do GLP-1 medications cause proportionally more muscle loss than other weight-loss interventions?
In the STEP 1 Study — semaglutide's primary clinical trial — researchers examined body composition changes in a subgroup of participants. Over 68 weeks, those taking semaglutide lost an average of 16.86% of their body weight [3].
This weight loss included a lean body mass loss of 3.61%.
Without context, that number is difficult to evaluate. A separate study, specifically designed to examine how different weight-loss approaches affect lean body mass, compared three groups: one placed on a calorie-restriction diet, a second using calorie restriction plus exercise, and a third doing exercise only.
The calorie-restriction-only group lost approximately 7% of their body weight. This included lean mass loss of around 2% in the upper body and 4% in the lower body [4].
Comparing the two studies: semaglutide produced approximately 17% total weight loss with 3.61% lean mass loss. Calorie restriction alone produced 7% total weight loss with 2–4% lean mass loss. Given that the semaglutide group lost considerably more weight overall, their proportional lean mass loss was actually lower than might be expected, and comparable to or better than the calorie-restriction-only group.
So while the evidence does confirm that GLP-1 medications lead to some lean mass loss, this is not a unique pharmacological hazard — it is a normal part of any significant weight-loss process.
Crucially, the comparison study also found that the group using calorie restriction plus exercise lost significantly less lean mass than the diet-only group — approximately 1% in the upper body and 2% in the lower body, compared to 2% and 4% respectively [5]. Adding exercise cut lean mass loss approximately in half. This is exactly why resistance training and adequate dietary protein are strongly recommended alongside any weight-loss programme — and especially alongside GLP-1 medications.
2. Thyroid Cancer
A second concern involves thyroid cancer. Early preclinical studies in rodents found that semaglutide could cause a form of thyroid cancer. However, effects observed in rodent models frequently do not translate to human populations — the biology and receptor distribution differ meaningfully. The relevant question is what the human evidence shows.
A meta-analysis examining 10 randomised controlled trials involving over 14,000 people concluded there is no significant risk of thyroid cancer associated with semaglutide [6].
A broader analysis incorporating both clinical trial data and real-world observational studies reached the same conclusion [7].
Based on the current body of human evidence, thyroid cancer does not appear to be a meaningful risk with semaglutide at clinically used doses.
3. Pancreatitis
Pancreatitis — inflammation of the pancreas, the organ responsible for producing digestive enzymes and hormones including insulin — is listed as a possible side effect for semaglutide. But how clinically significant is that risk in practice?
A meta-analysis examining adverse effects across existing GLP-1 clinical trials found that pancreatitis was no more common among those taking these medications than among those who were not [8].
This does not mean pancreatitis is impossible — it appears in prescribing information as a precaution for sound reasons. But the meta-analytic data does not support the concern that GLP-1 medications meaningfully elevate pancreatitis risk at the population level.
4. Gallstones
Unlike the risks discussed above, gallstones represent a genuinely elevated concern. Studies show that people taking GLP-1 medicines do have a higher risk of developing gallstones and other gallbladder problems [9], and this finding has been replicated consistently enough to take seriously.
The meta-analysis found those using GLP-1 medications had a 27% higher relative risk of developing a gallstone.
It helps to place this in absolute terms. Gallstones are quite common — an estimated 10–20% of Americans will develop them at some point in their lives [10], and the majority are symptom-free. Taking a midpoint figure of 15% baseline risk and increasing it by 27% gives an approximate risk of around 19%. The absolute difference is modest, but it is a real, documented signal and should be factored openly into any prescribing or consent discussion.
Whether this elevated risk is acceptable depends heavily on the individual's overall health profile and the seriousness of their obesity — a calculation that requires proper medical assessment, not a questionnaire.
5. Mental Health
Some reports — amplified considerably on social media — have suggested GLP-1 medications may cause depression or suicidal thoughts. The clinical evidence does not support this concern. An analysis of several major semaglutide trials found no difference in symptoms of depression or suicidal ideation between participants taking the medication and those receiving a placebo [11].
That analysis specifically examined the topic because of public concern, making its null finding particularly meaningful. As always, any individual experiencing changes in mental health while on a medication should discuss this promptly with their prescribing clinician — but the population-level data does not indicate a causal link.
Section 3: Risk and Benefit in Context
Reviewing the five misconceptions: lean mass loss is real but proportionally no worse than with other weight-loss approaches, and largely mitigated by resistance training. The thyroid cancer and pancreatitis fears are not supported by current human evidence. The depression and suicidal ideation concern has been directly studied and not confirmed. Gallstone risk is the exception — it is genuinely elevated, though the absolute increase is modest.
The honest picture on side effects is this: GLP-1 medications do commonly cause side effects. The most frequently reported are nausea, vomiting, diarrhoea, and constipation [12]. These gastrointestinal symptoms are typically mild to moderate in severity and tend to improve over time as the body adjusts to the medication — though for some patients they remain problematic enough to require dose adjustment or discontinuation. And as noted, there are some more serious side effects, like gallstones, that are real possibilities requiring informed consent and ongoing monitoring.
Careful, regular monitoring allows clinicians to detect problems early and respond appropriately. But monitoring cannot eliminate all risk — it can only help manage it.
Framing the decision around side effects alone, however, gives an incomplete picture. Equally important is asking: What are the health risks of not treating obesity?
GLP-1 medications are typically only considered at a BMI of 30 or above — a threshold defined by the clinical guidelines, not arbitrarily. At that level, the research is unambiguous: elevated BMI carries serious health consequences. Above a BMI of 25, the risk of death from all causes was approximately 30% higher for every 5-unit increase in BMI [13].
A high BMI is associated with a broad range of serious health problems including heart disease, type 2 diabetes, certain cancers, sleep apnoea, and joint disease. As one major study put it, an elevated BMI is connected to almost every category of mortality outcome [14].
Obesity poses serious, well-documented risks. The higher the BMI, the greater those risks become — and the less effective lifestyle modification alone tends to be at reversing them.
Achieving and sustaining significant weight loss through lifestyle changes alone is genuinely difficult. Research shows people typically lose between 5–7% of their body weight through diet and lifestyle modifications, and many struggle to maintain even this over the long term [15]. For those with a BMI above 30, a more structured and often more pharmacologically supported approach is frequently necessary to reach clinically meaningful goals.
This context is essential when evaluating whether GLP-1 medications are worth their risks. The medications carry documented potential risks. But untreated obesity at BMI 30+ carries risks that are more severe, more certain, and harder to address by other means. The decision ultimately rests with the individual patient — but it should be a fully informed decision, supported by a clinician who presents both sides of the ledger honestly and comprehensively.
Section 4: Tirzepatide — The Newer Option
One additional development is worth knowing about for anyone researching weight-loss medications: there is a newer agent similar to semaglutide but with a distinct pharmacological mechanism.
Standard GLP-1 medications like semaglutide work by mimicking a naturally occurring gut hormone. The molecule binds to GLP-1 receptors on certain cells and helps regulate both blood sugar and appetite signalling. The newer medication, however, acts on two different receptor types simultaneously — both GLP-1 receptors and GIP (glucose-dependent insulinotropic peptide) receptors. This dual agonist mechanism appears to produce a stronger overall effect on appetite suppression and metabolic regulation. According to current evidence, it produces significantly greater weight loss than semaglutide in head-to-head comparisons [16].
This newer medication is called tirzepatide. It is marketed under the brand name Mounjaro (originally approved for type 2 diabetes management) and Zepbound (approved specifically for weight management in individuals with obesity or overweight with weight-related health conditions). Anyone currently exploring GLP-1 weight-loss medications would do well to discuss tirzepatide as an option alongside semaglutide when speaking with a prescribing physician — particularly given the stronger weight-loss outcomes observed in trials so far.
Conclusion
As effective as the newest weight-loss medications are, diet and lifestyle changes remain the foundation of long-term weight management. Clinical guidelines specify starting with lifestyle modifications and only considering medication after those have been genuinely tried. Even for patients taking GLP-1 medications, a healthier diet — and the addition of resistance training to protect lean muscle mass — remains essential for sustainable results.
The evidence on GLP-1 medications is substantial and broadly supportive for appropriately selected patients. The most common fears — about thyroid cancer, pancreatitis, and depression — are not supported by current human evidence at the population level. The real risks (gallstones, gastrointestinal side effects, and the need for long-term use) are real and should be discussed honestly. And the risks of untreated obesity at BMI 30+ are serious enough to make that a genuine and clinically important comparison.
The key throughout is appropriate patient selection, full and honest counselling about what treatment involves, and ongoing monitoring by a clinician who follows best-practice guidelines rather than treating prescriptions as a revenue stream.
Reference List
Below are the study links in the order they appeared in this article:
- https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14725
- https://www.sciencealert.com/experts-are-concerned-drugs-like-ozempic-may-cause-muscle-loss
- https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5161655/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5161655/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11050669/
- https://pubmed.ncbi.nlm.nih.gov/37531876/
- https://onlinelibrary.wiley.com/doi/10.1111/obr.13717
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8961394/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3343155/
- https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2823084
- https://www.uptodate.com/contents/obesity-in-adults-drug-therapy
- https://www.uptodate.com/contents/obesity-in-adults-overview-of-management
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6249991/
- https://www.uptodate.com/contents/obesity-in-adults-overview-of-management
- https://www.uptodate.com/contents/obesity-in-adults-drug-therapy
